![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CTNNA2 |
Gene summary for CTNNA2 |
![]() |
Gene information | Species | Human | Gene symbol | CTNNA2 | Gene ID | 1496 |
Gene name | catenin alpha 2 | |
Gene Alias | CAP-R | |
Cytomap | 2p12 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P26232 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1496 | CTNNA2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.77e-04 | 2.19e-01 | 0.0155 |
1496 | CTNNA2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.98e-04 | 2.47e-01 | -0.1808 |
1496 | CTNNA2 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.53e-09 | 8.38e-01 | 0.0216 |
1496 | CTNNA2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.02e-10 | 4.99e-01 | -0.0811 |
1496 | CTNNA2 | HTA11_347_2000001011 | Human | Colorectum | AD | 7.45e-04 | 2.16e-01 | -0.1954 |
1496 | CTNNA2 | HTA11_411_2000001011 | Human | Colorectum | SER | 3.02e-04 | 4.69e-01 | -0.2602 |
1496 | CTNNA2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.61e-07 | 4.38e-01 | -0.1207 |
1496 | CTNNA2 | HTA11_696_2000001011 | Human | Colorectum | AD | 9.52e-26 | 5.38e-01 | -0.1464 |
1496 | CTNNA2 | HTA11_866_2000001011 | Human | Colorectum | AD | 5.11e-07 | 2.72e-01 | -0.1001 |
1496 | CTNNA2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 6.71e-13 | 8.44e-01 | -0.059 |
1496 | CTNNA2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.77e-05 | 5.09e-01 | -0.1706 |
1496 | CTNNA2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 9.71e-04 | 4.23e-01 | -0.2061 |
1496 | CTNNA2 | HTA11_5216_2000001011 | Human | Colorectum | SER | 8.30e-11 | 6.37e-01 | -0.1462 |
1496 | CTNNA2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.98e-30 | 2.67e+00 | 0.0338 |
1496 | CTNNA2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.13e-29 | 1.18e+00 | 0.0674 |
1496 | CTNNA2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 5.72e-04 | 5.59e-01 | 0.2585 |
1496 | CTNNA2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.64e-05 | 2.56e-01 | 0.3005 |
1496 | CTNNA2 | A015-C-203 | Human | Colorectum | FAP | 1.39e-14 | 7.63e-01 | -0.1294 |
1496 | CTNNA2 | A002-C-201 | Human | Colorectum | FAP | 7.49e-06 | 5.41e-01 | 0.0324 |
1496 | CTNNA2 | A001-C-119 | Human | Colorectum | FAP | 3.06e-02 | 4.63e-01 | -0.1557 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0007015 | Colorectum | AD | actin filament organization | 167/3918 | 442/18723 | 1.65e-16 | 7.94e-14 | 167 |
GO:0032535 | Colorectum | AD | regulation of cellular component size | 142/3918 | 383/18723 | 1.74e-13 | 3.41e-11 | 142 |
GO:1902903 | Colorectum | AD | regulation of supramolecular fiber organization | 139/3918 | 383/18723 | 2.01e-12 | 3.19e-10 | 139 |
GO:0032970 | Colorectum | AD | regulation of actin filament-based process | 142/3918 | 397/18723 | 4.05e-12 | 5.90e-10 | 142 |
GO:0110053 | Colorectum | AD | regulation of actin filament organization | 108/3918 | 278/18723 | 5.02e-12 | 6.98e-10 | 108 |
GO:0008154 | Colorectum | AD | actin polymerization or depolymerization | 90/3918 | 218/18723 | 6.14e-12 | 8.23e-10 | 90 |
GO:0032271 | Colorectum | AD | regulation of protein polymerization | 94/3918 | 233/18723 | 1.01e-11 | 1.29e-09 | 94 |
GO:0030041 | Colorectum | AD | actin filament polymerization | 81/3918 | 191/18723 | 1.35e-11 | 1.69e-09 | 81 |
GO:0051258 | Colorectum | AD | protein polymerization | 112/3918 | 297/18723 | 1.85e-11 | 2.27e-09 | 112 |
GO:0043254 | Colorectum | AD | regulation of protein-containing complex assembly | 148/3918 | 428/18723 | 2.64e-11 | 3.18e-09 | 148 |
GO:0008064 | Colorectum | AD | regulation of actin polymerization or depolymerization | 79/3918 | 188/18723 | 4.17e-11 | 4.74e-09 | 79 |
GO:0030833 | Colorectum | AD | regulation of actin filament polymerization | 74/3918 | 172/18723 | 4.50e-11 | 5.03e-09 | 74 |
GO:0030832 | Colorectum | AD | regulation of actin filament length | 79/3918 | 189/18723 | 5.71e-11 | 6.27e-09 | 79 |
GO:1902905 | Colorectum | AD | positive regulation of supramolecular fiber organization | 85/3918 | 209/18723 | 5.95e-11 | 6.33e-09 | 85 |
GO:0032956 | Colorectum | AD | regulation of actin cytoskeleton organization | 127/3918 | 358/18723 | 1.03e-10 | 1.04e-08 | 127 |
GO:0051495 | Colorectum | AD | positive regulation of cytoskeleton organization | 89/3918 | 226/18723 | 1.61e-10 | 1.56e-08 | 89 |
GO:0032273 | Colorectum | AD | positive regulation of protein polymerization | 62/3918 | 138/18723 | 1.94e-10 | 1.76e-08 | 62 |
GO:0031334 | Colorectum | AD | positive regulation of protein-containing complex assembly | 91/3918 | 237/18723 | 4.78e-10 | 3.99e-08 | 91 |
GO:0030838 | Colorectum | AD | positive regulation of actin filament polymerization | 48/3918 | 99/18723 | 9.21e-10 | 7.03e-08 | 48 |
GO:0010639 | Colorectum | AD | negative regulation of organelle organization | 114/3918 | 348/18723 | 1.41e-07 | 6.49e-06 | 114 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0467026 | Endometrium | AEH | Leukocyte transendothelial migration | 37/1197 | 114/8465 | 4.51e-07 | 6.11e-06 | 4.47e-06 | 37 |
hsa043909 | Endometrium | AEH | Hippo signaling pathway | 38/1197 | 157/8465 | 4.79e-04 | 3.38e-03 | 2.47e-03 | 38 |
hsa0521314 | Endometrium | AEH | Endometrial cancer | 18/1197 | 58/8465 | 7.42e-04 | 5.03e-03 | 3.68e-03 | 18 |
hsa05100111 | Endometrium | AEH | Bacterial invasion of epithelial cells | 32/1197 | 77/8465 | 3.28e-09 | 5.91e-08 | 4.33e-08 | 32 |
hsa04520111 | Endometrium | AEH | Adherens junction | 36/1197 | 93/8465 | 3.49e-09 | 5.98e-08 | 4.37e-08 | 36 |
hsa04670111 | Endometrium | AEH | Leukocyte transendothelial migration | 37/1197 | 114/8465 | 4.51e-07 | 6.11e-06 | 4.47e-06 | 37 |
hsa0439014 | Endometrium | AEH | Hippo signaling pathway | 38/1197 | 157/8465 | 4.79e-04 | 3.38e-03 | 2.47e-03 | 38 |
hsa0521315 | Endometrium | AEH | Endometrial cancer | 18/1197 | 58/8465 | 7.42e-04 | 5.03e-03 | 3.68e-03 | 18 |
hsa0452026 | Endometrium | EEC | Adherens junction | 36/1237 | 93/8465 | 8.57e-09 | 1.48e-07 | 1.11e-07 | 36 |
hsa0510027 | Endometrium | EEC | Bacterial invasion of epithelial cells | 30/1237 | 77/8465 | 1.26e-07 | 1.88e-06 | 1.40e-06 | 30 |
hsa0467027 | Endometrium | EEC | Leukocyte transendothelial migration | 36/1237 | 114/8465 | 2.97e-06 | 3.91e-05 | 2.91e-05 | 36 |
hsa0439023 | Endometrium | EEC | Hippo signaling pathway | 39/1237 | 157/8465 | 4.54e-04 | 3.47e-03 | 2.59e-03 | 39 |
hsa0521323 | Endometrium | EEC | Endometrial cancer | 17/1237 | 58/8465 | 2.97e-03 | 1.71e-02 | 1.28e-02 | 17 |
hsa0452035 | Endometrium | EEC | Adherens junction | 36/1237 | 93/8465 | 8.57e-09 | 1.48e-07 | 1.11e-07 | 36 |
hsa0510036 | Endometrium | EEC | Bacterial invasion of epithelial cells | 30/1237 | 77/8465 | 1.26e-07 | 1.88e-06 | 1.40e-06 | 30 |
hsa0467036 | Endometrium | EEC | Leukocyte transendothelial migration | 36/1237 | 114/8465 | 2.97e-06 | 3.91e-05 | 2.91e-05 | 36 |
hsa0439033 | Endometrium | EEC | Hippo signaling pathway | 39/1237 | 157/8465 | 4.54e-04 | 3.47e-03 | 2.59e-03 | 39 |
hsa0521333 | Endometrium | EEC | Endometrial cancer | 17/1237 | 58/8465 | 2.97e-03 | 1.71e-02 | 1.28e-02 | 17 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CTNNA2 | SNV | Missense_Mutation | rs778479901 | c.1756G>A | p.Ala586Thr | p.A586T | P26232 | protein_coding | tolerated(0.53) | benign(0.079) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CTNNA2 | SNV | Missense_Mutation | c.902N>T | p.Pro301Leu | p.P301L | P26232 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
CTNNA2 | SNV | Missense_Mutation | c.1498G>C | p.Val500Leu | p.V500L | P26232 | protein_coding | tolerated(0.14) | benign(0.275) | TCGA-AO-A1KR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
CTNNA2 | SNV | Missense_Mutation | c.2261N>T | p.Arg754Leu | p.R754L | P26232 | protein_coding | deleterious(0) | possibly_damaging(0.787) | TCGA-AR-A1AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CTNNA2 | SNV | Missense_Mutation | rs529691509 | c.2792N>A | p.Arg931Gln | p.R931Q | P26232 | protein_coding | deleterious(0.04) | probably_damaging(0.957) | TCGA-AR-A5QN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
CTNNA2 | SNV | Missense_Mutation | c.441G>A | p.Met147Ile | p.M147I | P26232 | protein_coding | tolerated(0.31) | benign(0.003) | TCGA-B6-A408-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
CTNNA2 | SNV | Missense_Mutation | c.1081N>T | p.Pro361Ser | p.P361S | P26232 | protein_coding | tolerated(0.74) | benign(0.045) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CTNNA2 | SNV | Missense_Mutation | c.1451N>C | p.Val484Ala | p.V484A | P26232 | protein_coding | tolerated(0.77) | benign(0.017) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CTNNA2 | SNV | Missense_Mutation | c.578N>T | p.Arg193Ile | p.R193I | P26232 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
CTNNA2 | SNV | Missense_Mutation | rs529691509 | c.2792G>A | p.Arg931Gln | p.R931Q | P26232 | protein_coding | deleterious(0.04) | probably_damaging(0.957) | TCGA-E9-A1R0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1496 | CTNNA2 | NA | Tumor necrosis factor alpha (TNF-alpha) inhibitors | 27670765 |
Page: 1 |